← back to search

Ratnakar Pingili

Novartis (United States) · US
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Polyomavirus and related diseases, and SARS-CoV-2 and COVID-19 Research.
h-index
7
citations
983
works
21
NIH funding
—
primary concept
Ofatumumab
email
✉ Find email ↗

Recent publications

Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Multiple Sclerosis Journal 2022cited by 95position: middledoi
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
Multiple Sclerosis Journal 2022cited by 76position: middledoi
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Neurology and Therapy 2022cited by 26position: middledoi
Ofatumumab versus Teriflunomide in Multiple Sclerosis
New England Journal of Medicine 2020cited by 682position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anne H. Cross · Washington University in St. Louis4 papers (2020–2022)Xavier Montalbán · Fundació ACE3 papers (2020–2022)Roman Willi · Novartis (Switzerland)3 papers (2020–2022)Wendy Su · Novartis (Switzerland)3 papers (2022–2022)Ludwig Kappos · Department of Biomedicine Basel3 papers (2020–2022)Dieter A. Häring · Novartis (Switzerland)3 papers (2020–2022)Bingbing Li · Third Affiliated Hospital of Zhengzhou University2 papers (2020–2022)Stephen L. Hauser · University of California, San Francisco2 papers (2022–2022)Bernd C. Kieseier · Novartis (Switzerland)2 papers (2022–2022)Ronald Zielman · Novartis (Switzerland)2 papers (2022–2022)Kevin Winthrop · Ohio University2 papers (2022–2022)Heinz Wiendl · JDSU (United States)2 papers (2020–2022)Ayan Das Gupta · Novartis (Switzerland)2 papers (2022–2022)Linda Mancione · Novartis (Switzerland)2 papers (2022–2022)Amit Bar‐Or · University of California System2 papers (2020–2022)Cécile Kerloëguen · Novartis (Switzerland)1 papers (2020–2020)Roseanne Sullivan · McGill University Health Centre1 papers (2022–2022)Morten Bagger · Novartis (Switzerland)1 papers (2022–2022)Martin Merschhemke · Novartis (Switzerland)1 papers (2020–2020)— · 1 papers (2022–2022)